Bicara Therapeutics Inc.
BCAX
$24.28
$0.652.75%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 63.22% | 56.43% | 62.54% | 92.40% | 102.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 66.84% | 59.98% | 88.87% | 103.23% | 107.52% |
| Operating Income | -66.84% | -59.98% | -88.87% | -103.23% | -107.52% |
| Income Before Tax | -80.88% | -70.64% | -103.12% | -103.74% | -57.88% |
| Income Tax Expenses | -33.55% | -23.64% | 16.04% | 5,733.33% | 5,066.67% |
| Earnings from Continuing Operations | -80.54% | -70.38% | -102.88% | -104.31% | -58.34% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -80.54% | -70.38% | -102.88% | -104.31% | -58.34% |
| EBIT | -66.84% | -59.98% | -88.87% | -103.23% | -107.52% |
| EBITDA | -66.80% | -59.95% | -88.87% | -103.28% | -107.56% |
| EPS Basic | 2.58% | 87.21% | 93.68% | 96.24% | 96.70% |
| Normalized Basic EPS | 2.52% | 87.23% | 93.69% | 96.25% | 96.70% |
| EPS Diluted | 2.58% | 87.21% | 93.68% | 96.24% | 96.70% |
| Normalized Diluted EPS | 2.52% | 87.23% | 93.69% | 96.25% | 96.70% |
| Average Basic Shares Outstanding | 36.73% | 86.41% | 226.99% | 1,565.51% | 6,160.20% |
| Average Diluted Shares Outstanding | 36.73% | 86.41% | 226.99% | 1,565.51% | 6,160.20% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |